Role of stromal cell-derived factor-1 in patients with non-ST elevation acute coronary syndrome

International Heart Journal

Volumn 55, Issue 3, 2014, Pages 219-227

  Tong, Guoxin ^a,b   Wang, Ningfu ^b   Zhou, Yujie ^a   Leng, Jianhang ^b   Gao, Wei ^b   Tong, Xiaoshan ^b   Shen, Yun ^b   Yang, Jianmin ^b   Ye, Xianhua ^b   Zhou, Liang ^b   Gao, Yan ^b  

^a CAPITAL MEDICAL UNIVERSITY   (China)

^b NANJING MEDICAL UNIVERSITY   (China)

Author keywords

Natriuretic peptide; Prognosis; Ventricular remodeling

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; C REACTIVE PROTEIN; CREATINE KINASE; STROMAL CELL DERIVED FACTOR 1; TROPONIN I;

ADULT; AGED; ANGIOCARDIOGRAPHY; ARTICLE; BLOOD CLOT LYSIS; CONTROLLED STUDY; CORONARY ARTERY OBSTRUCTION; ECHOCARDIOGRAPHY; ENZYME LINKED IMMUNOSORBENT ASSAY; GLOMERULUS FILTRATION RATE; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE ENDDIASTOLIC VOLUME; HEART LEFT VENTRICLE ENDSYSTOLIC VOLUME; HEART VENTRICLE REMODELING; HUMAN; KILLIP CLASS; MAJOR CLINICAL STUDY; MALE; NEPHELOMETRY; NON ST SEGMENT ELEVATION ACUTE CORONARY SYNDROME; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; REVASCULARIZATION; SCORING SYSTEM; SENSITIVITY AND SPECIFICITY; TWO DIMENSIONAL ECHOCARDIOGRAPHY;

ACUTE CORONARY SYNDROME; AGED; BIOLOGICAL MARKERS; CHEMOKINE CXCL12; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAPHY; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; RETROSPECTIVE STUDIES; ROC CURVE; VENTRICULAR REMODELING;

EID: 84901507215     PISSN: 13492365     EISSN: 13493299     Source Type: Journal    
DOI: 10.1536/ihj.13-289     Document Type: Article

References (37)

1. Palazzuoli A, Carrera A, Calabria P, et al. Brain natriuretic peptide levels during cardiac reperfusion: comparison between percutaneous coronary angioplasty and aorto-coronaric bypass. Clin Chim Acta 2004; 342: 87-92.
2. Pfeffer MA, Lamas GA, Vaughan DE, Parisi AF, Braunwald E. Effect of captopril on progressive ventricular dilatation after anterior myocardial infarction. N Engl J Med 1988; 319: 80-6.
3. Senior R, Basu S, Kinsey C, Schaeffer S, Lahiri A. Carvedilol prevents remodeling in patients with left ventricular dysfunction after acute myocardial infarction. Am Heart J 1999; 137: 646-52.
4. Farah E, Cogni AL, Minicucci MF, et al. Prevalence and predictors of ventricular remodeling after anterior myocardial infarction in the era of modern medical therapy. Med Sci Monit 2012; 18: CR276-81.
5. Sezer M, Aslanger EK, Cimen AO, et al. Concurrent microvascular and infarct remodeling after successful reperfusion of ST-elevation acute myocardial infarction. Circ Cardiovasc Interv 2010; 3: 208-15.
6. Richards AM, Doughty R, Nicholls MG, et al. Plasma N-terminal pro-brain natriuretic peptide and adrenomedullin: prognostic utility and prediction of benefi t from carvedilol in chronic ischemic left ventricular dysfunction. Australia-New Zealand Heart Failure Group. J Am Coll Cardiol 2001; 37: 1781-7.
7. Jaberg L, Toggweiler S, Puck M, et al. Prognostic value of N-terminal pro-B-type natriuretic peptide in patients with acute coronary syndromes undergoing left main percutaneous coronary intervention. Circ J 2011; 75: 2648-53.
8. Hu X, Dai S, Wu WJ, et al. Stromal cell derived factor-1 alpha confers protection against myocardial ischemia/reperfusion injury: Role of the cardiac stromal cell derived factor-1 alpha cxcr4 axis. Circulation 2007; 116: 654-63.
9. Elmadbouh I, Haider H, Jiang S, Idris NM, Lu G, Ashraf M. Ex vivo delivered stromal cell-derived factor-1alpha promotes stem cell homing and induces angiomyogenesis in the infarcted myocardium. J Mol Cell Cardiol 2007; 42: 792-803.
10. Saxena A, Fish JE, White MD, et al. Stromal cell-derived factor- 1alpha is cardioprotective after myocardial infarction. Circulation 2008; 117: 2224-31.
11. Frederick JR, Fitzpatrick JR 3rd, McCormick RC, et al. Stromal cell-derived factor-1alpha activation of tissue-engineered endothelial progenitor cell matrix enhances ventricular function after myocardial infarction by inducing neovasculogenesis. Circulation 2010; 122: S107-17.
12. Choi JO, Kim EY, Lee GY, et al. Predictors of left ventricular reverse remodeling and subsequent outcome in nonischemic dilated cardiomyopathy. Circ J 2013; 77: 462-9.
13. Antman EM, Cohen M, Bernink PJ, et al. The TIMI risk score for unstable angina/non-ST elevation MI: A method for prognostication and therapeutic decision making. JAMA 2000; 284: 835-42.
14. Smilde TD, van Veldhuisen DJ, Navis G, Voors AA, Hillege HL. Drawbacks and prognostic value of formulas estimating renal function in patients with chronic heart failure and systolic dysfunction. Circulation 2006; 114: 1572-80.
15. Lang RM, Bierig M, Devereux RB, et al. Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantifi cation Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr 2005; 18: 1440-63.
16. Bolognese L, Neskovic AN, Parodi G, et al. Left ventricular remodeling after primary coronary angioplasty: patterns of left ventricular dilation and long-term prognostic implications. Circulation 2002; 106: 2351-7.
17. Hanley JA, McNeil BJ. A method of comparing the areas under receiver operating characteristic curves derived from the same cases. Radiology 1983; 148: 839-43.
18. Chang LT, Yuen CM, Sun CK, et al. Role of stromal cell-derived factor-1alpha, level and value of circulating interleukin-10 and endothelial progenitor cells in patients with acute myocardial infarction undergoing primary coronary angioplasty. Circ J 2009; 73: 1097-104.
19. Ceradini DJ, Kulkarni AR, Callaghan MJ, et al. Progenitor cell traffi cking is regulated by hypoxic gradients through hif-1 induction of sdf-1. Nat Med 2004; 10: 858-64.
20. Doughty RN, Whalley GA, Gamble G, MacMahon S, Sharpe N. Left ventricular remodeling with carvedilol in patients with congestive heart failure due to ischemic heart disease. Australia-New Zealand Heart Failure Research Collaborative Group. J Am Coll Cardiol 1997; 29: 1060-6.
21. Wessler BS, Kramer DG, Kelly JL, et al. Drug and device effects on peak oxygen consumption, 6-minute walk distance, and natriuretic peptides as predictors of therapeutic effects on mortality in patients with heart failure and reduced ejection fraction. Circ Heart Fail 2011; 4: 578-88. (Review)
22. Lee BC, Hsu HC, Tseng WY, et al. Effect of cardiac rehabilitation on angiogenic cytokines in postinfarction patients. Heart 2009; 95: 1012-8.
23. Stellos K, Bigalke B, Langer H, et al. Expression of stromal-cellderived factor-1 on circulating platelets is increased in patients with acute coronary syndrome and correlates with the number of CD34+ progenitor cells. Eur Heart J 2009; 30: 584-93.
24. Richard DE, Berra E, Pouyssegur J. Nonhypoxic pathway mediates the induction of hypoxia-inducible factor 1alpha in vascular smooth muscle cells. J Biol Chem 2000; 275: 26765-71.
25. Gorlach A, Diebold I, Schini-Kerth VB, et al. Thrombin activates the hypoxia-inducible factor-1 signaling pathway in vascular smooth muscle cells: Role of the p22(phox)-containing NADPH oxidase. Circ Res 2001; 89: 47-54.
26. Page EL, Robitaille GA, Pouyssegur J, Richard DE. Induction of hypoxia-inducible factor-1alpha by transcriptional and translational mechanisms. J Biol Chem 2002; 277: 48403-9.
27. Sabatine MS, Morrow DA, de Lemos JA, et al. Multimarker approach to risk stratification in non-ST elevation acute coronary syndromes: simultaneous assessment of troponin I, C-reactive protein, and B-type natriuretic peptide. Circulation 2002; 105: 1760-3.
28. Cohn JN, Ferrari R, Sharpe N. Cardiac remodeling -- concepts and clinical implications: a consensus paper from an international forum on cardiac remodeling. Behalf of an International Forum on Cardiac Remodeling. J Am Coll Cardiol 2000; 35: 569-82.(Review)
29. Cintron G, Johnson G, Francis G, Cobb F, Cohn JN. Prognostic signifi cance of serial changes in left ventricular ejection fraction in patients with congestive heart failure. The V-HeFT VA Cooperative Studies Group. Circulation 1993; 87: VI17-23.
30. White HD, Norris RM, Brown MA, Brandt PW, Whitlock RM, Wild CJ. Left ventricular end-systolic volume as the major determinant of survival after recovery from myocardial infarction. Circulation 1987; 76: 44-51.
31. Huang C, Gu H, Zhang W, Manukyan MC, Shou W, Wang M. SDF-1/CXCR4 mediates acute protection of cardiac function through myocardial STAT3 signaling following global ischemia/ reperfusion injury. Am J Physiol Heart Circ Physiol 2011; 301: H1496-505.
32. Ionova IA, Vasquez-Vivar J, Cooley BC, et al. Cardiac myocytespecifi c overexpression of human GTP cyclohydrolase I protects against acute cardiac allograft rejection. Am J Physiol Heart Circ Physiol 2010; 299: H88-96.
33. Lakkisto P, Kyto V, Forsten H, et al. Heme oxygenase-1 and carbon monoxide promote neovascularization after myocardial infarction by modulating the expression of HIF-1alpha, SDF-1alpha and VEGF-b. Eur J Pharmacol 2010; 635: 156-64.
34. Tillmanns J, Rota M, Hosoda T, et al. Formation of large coronary arteries by cardiac progenitor cells. Proc Natl Acad Sci U S A 2008; 105: 1668-73.
35. Guo WY, Zhang DX, Li WJ, et al. Akt-centered amplifi cation loop plays a critical role in vascular endothelial growth factor/stromal cell-derived factor 1-α cross-talk and cardioprotection. Chin Med J (Engl) 2011; 124: 3800-5.
36. Hohensinner PJ, Kaun C, Rychli K, et al. The infl ammatory mediator oncostatin M induces stromal derived factor-1 in human adult cardiac cells. FASEB J 2009; 23: 774-82.
37. Abbott JD, Ahmed HN, Vlachos HA, Selzer F, Williams DO. Comparison of outcome in patients with ST-elevation versus non- ST-elevation acute myocardial infarction treated with percutaneous coronary intervention (from the National Heart, Lung, and Blood Institute Dynamic Registry). Am J Cardiol 2007; 100: 190-5.